Summary
Vertex Pharmaceuticals Incorporated filed an amendment to its Form 8-K on February 13, 2006, clarifying previous filings and providing crucial updates on its clinical development programs. The amendment primarily focuses on the company's 2005 financial results, as detailed in a press release dated February 7, 2006. More significantly for investors, the filing announces the completion of a 28-day Phase II clinical study for VX-950, a protease inhibitor targeting Hepatitis C Virus (HCV) infection. The preliminary results for VX-950 are highly encouraging, showing a significant reduction in viral load. By the end of week 4 of dosing, all 12 patients in the study had undetectable levels of HCV RNA, with nine of them achieving this status by week 3. Importantly, no patients experienced viral breakthrough during the treatment period. Furthermore, supporting toxicology studies in animals have been successfully completed, clearing the way for longer duration clinical studies of VX-950.
Key Highlights
- 1Amendment to Form 8-K clarifies reporting of 2005 financial results.
- 2Vertex completed a 28-day Phase II clinical study for VX-950, a hepatitis C protease inhibitor.
- 3Preliminary results show significant viral load reduction in all 12 patients by the end of week 4 of VX-950 dosing.
- 4All 12 patients had undetectable HCV RNA by the end of the 4-week dosing period.
- 5Nine out of 12 patients achieved undetectable HCV RNA by week 3.
- 6No viral breakthrough was observed in patients during the study.
- 7Supporting three-month animal toxicology studies for VX-950 have also been successfully completed.